Customers tell us they want peace of mind so that if a consumer has their beverage across multiple day parts, they will have a large margin before hitting tolerance levels. Why beverage brands need to brace themselves The thirst for GLP-1 medication only looks set to increase among consumers with the launch of unfussy, non-injectable formats A pill version of the appetite-suppressing drug, Wegovy, was unveiled by pharma giant Novo Nordisk in January Eli Lilly & Co is preparing to debut its own oral version, Orforglipron, post-FDA approval later this year The total GLP-1 pill market is forecast to leap from $3.2bn in 2025 to 34.3 bn in 2031, a CAGR of 48.4% (GlobalData) (Source GlobalData) GLP-1 drink NPD outside the box Although, its not just traditional food and beverage companies developing tailored NPD
In the meantime, patients are already feeling the benefits
Stay in the middle
While lipotropic injections are considered safe for many patients, there are certain side effects that can occur, and there are some factors that may make a person ineligible to receive the injections
Florida Surgery & Weight Loss Center does not sell medications
Thats why we say: GLP-1s are just one piece of the puzzle
